Red light therapy with dual wavelengths (650nm and 850nm) can stimulate hair regrowth without DHT blockers. Consistent use of a panel with these wavelengths has shown positive results in hair regrowth.
User doing PRP with exosomes for hair loss, sees possible regrowth after two treatments. Another user suggests providing before and after pictures for better assessment.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Users question effectiveness of HMI-115 and consider waiting longer for results.
Microneedling, when combined with finasteride and topical minoxidil, can enhance hair regrowth for male pattern baldness, especially at the temples. Users report varying success with needle depths between 0.5mm and 1.5mm, with stamps preferred over rollers to minimize scalp damage.
Turmeric may slightly inhibit DHT, but it likely doesn't significantly impact hair loss. Creatine might increase DHT levels, but its effect on hair loss is debated and not conclusively proven.
User hoodoomoovoo discusses their interest in stem cell research and its potential for hair loss treatment. They share links to studies and mention ongoing trials, expressing optimism for a future solution to hair loss.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.
The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.
A user is concerned about hair thinning and is using minoxidil, considering finasteride, and planning blood tests to rule out deficiencies. They are advised to consult a dermatologist to confirm if androgenic alopecia is the cause before starting finasteride.
The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.
Fluridil may decrease the number of androgen receptors in hair follicles by up to 95%. This suggests a different action mechanism from other non-steroidal antiandrogens like RU58841, indicating they might be used together.
User experienced significant hair loss and tried treatments including Finasteride, Minoxidil, scalp massages, microneedling, and Nizoral shampoo. After focusing on overall physical and mental health, user saw dramatic improvement in hair growth.
The user is using a combination of topical and oral treatments containing Finasteride and Minoxidil, along with supplements like Biotin, Saw Palmetto, and vitamins, to combat hair loss. They are also incorporating lifestyle changes such as a whole foods diet, exercise, and improved sleep to support their regimen.
A user's successful hair transplant, with some people questioning the donor area regrowth, and others speculating that hair fibre may have been used to help fill in areas.
A user's 15-month experience with oral finasteride, minoxidil, zinc and vitamin C, caffeine, and microneedling as treatments for hair loss, which has yielded impressive results. Suggestions were made to stack a topical DHT blocker with the finasteride or increase the microneedling regimen, and it was suggested to re-evaluate at the two year mark.
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.
Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.
The conversation is about experiences with GHK-Cu Copper and AHK-Cu Copper for hair regrowth and thickening. One user expressed skepticism about its effectiveness.
The user discusses hair transplant results and questions the necessity of pairing microneedling with a special liquid, aside from minoxidil, for better hair thickening. They are skeptical about the doctor's recommendation and seek advice on whether the liquid is essential or a sales tactic.
MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.
Exploring potential treatments for hair loss, with the focus being on comparing RU58841 and Pyrilutamide. Finasteride, Dutasteride, oral Minoxidil, microneedling, topical Minoxidil, Biotin, Zinc, Vitamin D and Nizoral are also discussed as part of a treatment stack.
A user suggests that deeper microneedling with Verteporfin injections might help regrow hair in areas with scar tissue, alongside a DHT blocker. Another user explains that hair loss might be due to reduced Wnt/β-Catenin signaling and suggests that treatments like Minoxidil, Finasteride, and microneedling could potentially reverse it.
A new painless microneedle patch shows promise in reversing hair loss. The discussion focuses on potential new treatments beyond common options like Minoxidil, finasteride, and RU58841.
The user switched to oral dutasteride and minoxidil and is questioning the need for derma stamping, which is typically used with topical treatments. They are considering whether derma stamping is necessary with their current oral regimen.
The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.